Allarity Therapeutics, Inc. (NASDAQ: ALLR)

Allarity Therapeutics, Inc., often recognized by its ticker symbol ALLR, is a clinical-stage company operating in the pharmaceutical industry. The company specializes in precision medicine, with a particular focus on advancing in-licensed oncology therapeutics for patients grappling with challenging-to-treat cancers. Allarity's core technology is the Drug Response Predictor (DRP) platform, a proprietary tool that identifies patients who are most likely to derive clinical benefit from specific therapeutics.

The company's primary business activities revolve around the development of novel cancer therapeutics and companion diagnostics using its unique DRP platform. Allarity's main products include stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP) and Tankyrases, and dovitinib, a second-generation pan-tyrosine kinase inhibitor (TKI). The company's services primarily involve the development of companion diagnostics to identify patients most likely to respond to its therapeutic candidates.

Allarity's revenue generation is primarily tied to the development and commercialization of its therapeutic candidates. Its primary services include the development of companion diagnostics to identify patients most likely to respond to its therapeutic candidates. The company's customer base includes patients with advanced, recurrent ovarian cancer, as well as patients with other types of cancer who may benefit from its therapeutic candidates.

In the highly competitive pharmaceutical industry, Allarity's proprietary DRP platform provides a substantial competitive advantage for clinical and regulatory success for each of its therapeutic candidates. The company's ability to identify patients most likely to respond to its therapeutic candidates using its DRP platform has the potential to improve the overall clinical benefit in its clinical trials and thereby improve its chances for regulatory approval.

The company's position within the industry is characterized by its innovative approach to cancer therapy and its ability to identify patients most likely to respond to its therapeutic candidates using its proprietary DRP platform. Allarity's therapeutic candidates include stenoparib, a novel inhibitor of PARP and Tankyrases, and dovitinib, a second-generation pan-TKI.

Some of the company's notable products include stenoparib, dovitinib, Ixempra, and LiPlaCis. Stenoparib is a novel inhibitor of PARP and Tankyrases, enzymes critically important in the WNT pathway, which is commonly activated in many different cancers. The company is currently advancing a Phase 2 clinical trial of stenoparib for the treatment of ovarian cancer, using the stenoparib-specific DRP companion diagnostic.

Dovitinib is a second-generation pan-TKI, which was previously developed by Novartis. However, the FDA determined that the application for dovitinib was not sufficiently complete to permit a substantive review. The company has since decided to de-prioritize the development of dovitinib.

Ixempra is a liposomal anthracycline, which was previously developed by Sanofi. Allarity had acquired the rights to Ixempra, but has since decided to de-prioritize its development. LiPlaCis is a liposomal cisplatin, which was previously developed by Genmab. Allarity had acquired the rights to LiPlaCis, but has since decided to de-prioritize its development.

Allarity's DRP companion diagnostics platform is a proprietary, predictive biomarker technology that employs complex systems biology and bio-analytics with a proprietary clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. The company has retrospectively validated its DRP platform using retrospective observational studies in 35 clinical trials conducted or sponsored by other companies.

Allarity has received significant funding from its investors, including a $20 million private placement (PIPE financing) in May 2021. The company had approximately $40 million in cash and cash equivalents as of December 2021. In terms of its regulatory status, Allarity has submitted a NDA to the FDA for dovitinib, which was not accepted for filing. The company is currently advancing a Phase 2 clinical trial of stenoparib for the treatment of ovarian cancer, using the stenoparib-specific DRP companion diagnostic.